| Name | AHR antagonist 3 |
|---|---|
| Synonyms |
4-Pyridazinecboxamide, 6-(4-chlorophenyl)-2,3-dihydro-N-[(1S)-2-hydroxy-1-methylethyl]-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo
BAY 2416964, 10 mM in DMSO (S)-6-(4-chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-cboxamide BAY 2416964 //BP 6-(4-chlorophenyl)-N-[(2S)-1-hydroxypropan-2-yl]-2-(1-methylpyrazol-4-yl)-3-oxopyridazine-4-cboxamide BAY241696 |
| Description | AHR antagonist 3 is a 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compound and an aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 192, has an IC50 of 341 nM. AHR antagonist 3 has anti-cancer effects[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 341 nM (Aryl hydrocarbon receptor (AHR))[1] |
| In Vitro | AHR antagonist 3 (Example 192) induces AHR-regulated gene CYP1A1 expression in a human monocytic U937 cells with an IC50 of 4.3 nM[1]. |
| References |
| Density | 1.42±0.1 g/cm3(Predicted) |
|---|---|
| Molecular Formula | C18H18ClN5O3 |
| Molecular Weight | 387.82 |
| Hazard Codes | Xn |
|---|